Short answer
DaVita (DVA) filed its Q3 2025 10-Q quarterly report on Oct 29, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $3.4B (up 4.8% year over year) with net income of $150M.
Q3 2025 key financials · XBRL
- Revenue
- $3.4B
- +4.8% YoY · +1.2% QoQ
- Net income
- $150M
- −30.0% YoY · −24.6% QoQ
- Operating margin
- 14.8%
- EPS (diluted)
- $2.05
- −18.3% YoY · −20.2% QoQ
Source: XBRL data from the DaVita (DVA) Q3 2025 10-Q on SEC EDGAR. USD.
DaVita Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total consolidated revenue $10.02B YTD Q3 2025 vs. $9.52B YTD Q3 2024, up 5.3%; U.S. dialysis revenue $8.72B up 2.5%, ancillary services $1.36B up 25.5%
- U.S. dialysis operating income $1.53B YTD Q3 2025 vs. $1.63B YTD Q3 2024, down 5.9%; adjusted operating income $1.55B down 2.3%
- Best performing segment: International ancillary services revenue +36.2% YTD; worst: U.S. IKC operating loss increased to $24M from $48M loss YTD
- Operating cash flow $1.35B YTD, down 8.7%; free cash flow decreased 18.8% to $0 (value not explicitly given); repurchased 10M shares for $1.46B (+43.4% YoY)
- Management cautious due to cybersecurity incident and federal government shutdown impacting operations, expects continued expense pressures and operational uncertainties
Risk Factors
- No new or materially changed risk factors since 2024 10-K filing
- Regulatory risk from potential changes in Medicare and Medicaid reimbursement rates, ongoing impact on revenue stability
- Competitive risk from industry consolidation affecting market share and pricing power in dialysis services
- Operational risk from reliance on staffing and facility management affecting service continuity and patient care quality
- Financial risk from exposure to reimbursement rate fluctuations impacting cash flow and liquidity management
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other DaVita quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.